Here"s Why Sarepta Therapeutics Jumped 17% in September

Brent crude futures jumped close to $3 on Friday to their highest since September after a U.S. air strike killed key Iranian and Iraqi military personnel, raising concerns that escalating Middle East tensions may disrupt oil supplies......»»

Sarepta shares jumped last week on news that the company reached a licensing deal with Roche. While investors saw about a five-point bump from this news, one analyst sees much more upside for this........»»

Sarepta Therapeutics Inc (NASDAQ: SRPT) has entered a partnership with Roche (OTC: Latest Ratings for SRPT.....»»

Sarepta Therapeutics shares made a handy gain to start the week after it announced a licensing agreement with Roche for its investigational gene therapy for Duchenne muscular dystrophy......»»

Benzinga Pro's Stocks To Watch For Monday Sarepta Therapeutics (SRPT) - Shares were up about 9% Monday morning following news of a partnership with Roche (RRHBY) for its investigational read more.....»»

Roche Holding AG made its second major gene therapy deal in a year on Monday, spending $1.15 billion to obtain the rights to Sarepta Therapeutics Inc's investigational drug to treat duchenne muscular dystrophy (DMD) outside the United States......»»

Roche entered into a $1.15 billion licensing agreement with Sarepta Therapeutics to obtain the right to launch and commercialize Sarepta's investigational gene therapy for Duchenne muscular dystrophy (DMD) outside the United States......»»

The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and o.....»»

Prevail Therapeutics shares jumped early on Tuesday after the firm announced that the FDA has granted Orphan Drug designation for its dementia treatment......»»

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Sarepta Therapeutics (SRPT) has good news for SRPT stock investors concerning its tr.....»»

Midway through trading Friday, the Dow traded up 0.01% to 28,135 while the NASDAQ rose 0.27% to 8,740.48. The S&P also rose, gaining 0.03% to 3,169.63. Leading and Lagging Sectors I.....»»

Midway through trading Friday, the Dow traded up 0.01% to 28,135 while the NASDAQ rose 0.27% to 8,740.48. The S&P also rose, gaining 0.03% to 3,169.63. 0 read more.....»»

Sarepta shares jumped on Friday after the firm announced that the FDA has approved Vyondys 53 (golodirsen) for the treatment of Duchenne muscular dystrophy (DMD) in certain patients......»»

The FDA unexpectedly reversed course Thursday, approving the second treatment developed by Sarepta Therapeutics for the rare disease Duchenne muscular dystrophy just a few months after rejecting the drug.  Sarepta (Nasdaq: SRPT) announced Thursday even.....»»

Sarepta Therapeutics Inc. shares surged in the extended session Thursday after the genetic medicine company said the Food and Drug Admin.....»»

Fate Therapeutics shares jumped on Monday after the firm announced new preclinical data for its off-the-shelf, multi-antigen targeting natural killer cell product candidate derived from a clonal........»»

Zacks.....»»

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why.....»»

Protagonist Therapeutics shares jumped on Wednesday after the company announced preliminary results from its midstage study for patients with transfusion-dependent beta-thalassemia......»»

Axsome Therapeutics shares jumped early on Tuesday after the firm announced positive results from its midstage narcolepsy trial......»»